30 closest matches · ranked by relevance
Hypothalamic-pituitary-ovarian Axis, Gonadotropins, Ethinyl Estradiol, Contraceptive Efficacy
Primary: Follicle-stimulating Hormone — 5.01; 5.86; 6.38 milli international units per milliliter — p=0.88
Ovarian Suppression
Primary: Risk of Oral Contraceptive (OC) Failure Due to Less Contraceptive-mediated Ovarian Suppression. — 54; 28; 11; 12 Participants
Menopausal and Other Perimenopausal Disorders
Primary: Hot Flashes — 10.3; 7.944 scores on a scale
Pregnancy · Contraception
Primary: Part 1: Serum Medroxyprogesterone Acetate (MPA) Concentration at Day 1 — 0.36; 0.67 nanograms (ng)/milliliter (mL)
Ovulation (Follicular Rupture Yes/no) · Menstrual Cycles (Total Length, Bleeding Days) · Gonadotropin and Ovarian Hormone Levels (FSH, LH, E2, P)
Primary: Menstrual Cycle Length — 28.5; 27.2 Days
Ovulation Suppression
Primary: Ovulation Suppression in Three Treatment Groups Over 3 Cycles — 36.5; 20.7; 11.5; 36.9 %of cycles with possible ovulation
Normal · PCOS
Primary: LH Pulse Frequency — 1.31; 0.91; 1.33; 1.19 pulses/hour
Polycystic Ovary Syndrome
Primary: Change in Biochemical Hyperandrogenism From Baseline to 1 Month Post Yasmin Initiation — -15.38; -8.54 ng/dl
Estrogen Receptor Positive Breast Cancer · Progesterone Receptor Positive Tumor · Recurrent Breast Carcinoma
Primary: Disease-free Survival — 84.7; 86.6; 89 percentage of participants — p=0.1
Contraception
Primary: Number of Participants With Ovulation With Implant-alone — 7; 0 Participants
Ovulation · Luteal Development
Primary: Number of Cycles With Ovulation Dysfunction When Taken After Ovulation: Extended Luteal Phase — 1; 6; 5 Participants
Ovulation Disorder · Ovarian Cysts
Primary: Number of Participants With Progesterone Level Greater Than 1.5 ng/mL — 9; 10 Participants
Fertility · Contraception
Primary: Median Cervical Mucus Score - Baseline — 11; 13 score on a scale
Contraception
Primary: Percentage of Pregnancies Prevented (PPP) — 77.5; 36.9 percentage of pregnancies prevented — p=<0.0001
Premenstrual Dysphoric Disorder
Primary: Pre-Post Change in Premenstrual Symptom Severity — 1.93; 1.73; 1.64 units on a scale
Endometriosis · Unexplained Infertility
Primary: Number of Live Births — 3; 1 live births
Mood
Primary: Follicular Cycle Total Behavioral Score for Calendar of Premenstrual Experiences (COPE) Self Assessment — 3; 5 units on a scale
Oral Contraceptive
Primary: Breast Cell Proliferation Levels Between the Two Oral Contraceptive Dose Groups — 7.5; 12.4 Percent of cells staining for Ki67
Unexplained Infertility · Polycystic Ovarian Syndrome · Anovulatory
Primary: LH Surge — 9; 9 Participants
Contraception
Primary: Percentage of Participants With Ovulation Incidence, by Cycle — 0; 0; 0; 0 Percentage of Participants
Ovarian Hyperstimulation Syndrome
Primary: Volume of Ascites in the Abdomen is Indicative of the Severity of OHSS — 10 cc (volume of ascites)
Suicidal Ideation
Primary: Perimenstrual Change in Self-Injurious Thoughts and Behaviors Interview (SITBI) Suicidal Ideation Score — -.05; .35 units on a scale — p=.012
Amenorrhea · Premature Ovarian Failure · Ovarian Function Insufficiency
Primary: Number of Participants With Secondary Amenorrhea Following 3-month Depot Leuprolide — 37 participants
Primary Amenorrhea With Hypogonadotropic Hypogonadism
Primary: Ovulation Rate — 1; 4; 5; 9 Participants — p=0.0120
Epithelial Ovarian Cancer
Primary: Cell Proliferation in the Fallopian Tube Fimbriae as Measured by Ki-67%+ — 8.3 percentage of positively stained cells
Polycystic Ovary Syndrome
Primary: Biochemical Assessment of Hyperandrogenism — 0.7; 0.7 Index — p=<.0001
Metrorrhagia
Primary: Mean Number of Bleeding or Spotting Days — 16; 28 days
Dysmenorrhea
Primary: Change in Visual Analog Scale (VAS) Score — -74.8; -58.7 units on a scale — p=0.05
Contraception
Primary: Effect of Delayed Intake or Missed Pill on Cervical Mucus Score (CMS) — 1.0; 0.7; 0.1; 0.3 changes in scores on a scale — p=0.26
Menstruation Disturbances
Primary: Ovulation in Cycle 2 — 3; 2 Participants